Menu Search
Equities

Amarin Corporation PLC

AMRN:NMQ

Amarin Corporation PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.587
  • Today's Change-0.012 / -1.94%
  • Shares traded475.34k
  • 1 Year change-38.33%
  • Beta1.9325
Data delayed at least 15 minutes, as of Sep 20 2024 20:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold1
Sell2
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Amarin Corporation plc (ADR) have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a 67.06% increase from the last price of 0.5986.
High67.1%1.00
Med67.1%1.00
Low67.1%1.00

Earnings history & estimates in USD

On Jul 31, 2024, Amarin Corporation plc (ADR) reported 2nd quarter 2024 breakeven earnings per share. This result was in line with the consensus of the 4 analysts following the company and outperformed last year's 2nd quarter results by 0.04.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate-15.00%
Amarin Corporation plc (ADR) reported annual 2023 losses of -0.150 per share on Feb 29, 2024.
Average growth rate+35.44%
More ▼

Revenue history & estimates in USD

Amarin Corporation plc had 2nd quarter 2024 revenues of 67.49m. This bettered the 51.02m consensus of the 4 analysts covering the company. This was 21.50% below the prior year's 2nd quarter results.
Average growth rate-2.36%
Amarin Corporation plc had revenues for the full year 2023 of 306.91m. This was 16.87% below the prior year's results.
Average growth rate-3.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.